Summary
- Since March 2021, under the dynamic leadership of CEO and Director Mike O’Shea, Xcelerate Inc (OTCQB:XCRT) has achieved significant milestones. These accomplishments have driven the company’s progression from Shell status to Pink Current, and subsequently to its current OTCQB status with a future plan of uplisting to the New York Stock Exchange.(As stated in public interviews)
- Xcelerate has acquired a collection of licensed and patented intellectual property. As per their latest announcement, the company has substantially expanded its patent portfolio, securing patent rights in nine more countries, which now includes the EU, Russia, and Korea.
- Xcelerate has achieved noteworthy accomplishments, such as acquiring a 51% membership interest in AfiyaSasa Africa, LLC, and initiating the AfiyaSasa Africa Pilot Project in hospitals across Africa.
- Recently, Xcelerate, Inc. concluded the acquisition of a majority interest in ESN Group, Inc. and California Skin Research, Inc. (collectively referred to as the “ESN Group”). This acquisition encompasses a diverse portfolio of healthcare and skincare products, including the innovative Ceramedx® (www.ceramedx.com), the first natural plant-based ceramide therapy system designed in consultation with dermatologists for dry, sensitive skin, as well as Earth Science Beauty (www.earthsciencebeauty.com).
About Xcelerate Inc (OTC: XCRT stock).: Pioneering the Future of Healthcare Through Innovation
In the ever-changing landscape of healthcare, there are companies that stand out not only for their vision, but also for their immense impact. Xcelerate Inc. is certainly one such company, positioned to change the medical, health, and wellness industries with a visionary business plan that covers three unique yet intertwined branches.
1. Empowering Medical Technology: A World of Possibilities
2. Bridging Healthcare Gaps: Virtual Health for All
3. Beauty and Science Converge: Redefining Skincare
A Synergy of Expertise: The Xcelerate Management Advantage
In the driver’s seat of Xcelerate, you’ll find an exceptional management team with a wealth of experience and diverse expertise. Leading the pack is CEO and Director Mike O’Shea, a certified financial investigator and forensic accountant, who possesses a wealth of experience from his involvement with organizations like the US Secret Service, ATF, and other distinguished institutions. His extensive background emphasizes his in-depth comprehension of complex financial intricacies.
Joining the team as Director is Jason Householder, who also serves as the Co-Founder and CEO of Charlotte’s LenDRgroup Consulting. With over a decade devoted to healthcare banking, Jason specializes in crafting effective strategies for medical, dental, and veterinary practices. His insights help these practices navigate the complexities of business operations seamlessly.
Steve Gravely, presently the President of the Consulting Group at Jocassee, Inc., contributes significantly to the leadership. His remarkable track record includes spearheading 25 global manufacturing plants and overseeing the successful launch of over 300 new products for prominent industry giants like Michelin, AT&T, NCR, and General Motors. His expertise adds a distinctive dimension to the already extensive skill set of the management team.
Distinguished Advisory Board Members
Within Xcelerate Inc., an esteemed advisory board boasts the presence of eminent figures such as Dr. Barry Marshall, a distinguished Nobel laureate in the medical field. Alongside him stands the renowned neurosurgeon Dr. Dilan B. Ellegala, adding further depth to the board’s expertise. Also lending their insights is Dr. Anja Glisovic, a research scholar with a PhD in X Ray & Material Physics, contributing a unique perspective to the team.
In a recent addition, the advisory board extended a warm welcome to Cathy Scangarella, who currently holds the position of Chief Business Development Officer and Sector Lead for the Life Sciences at Choose New Jersey. With her involvement, the board continues to amass a wealth of industry knowledge, fortifying Xcelerate’s commitment to pioneering advancements in healthcare.
Current Ventures: Navigating Healthcare’s Frontier
1) Inventory of Patents Under Xcelerate Inc. Ownership and Acquisition.:
The collection includes four approved and one awaiting U.S. patents, along with two approved and one pending European patent. Additionally, the portfolio encompasses specific licensing agreements linked to research advancements from Cambridge University.
- U.S. 9,889,151: Techniques for treating certain cancers using a composition that releases orthosilicic acid in the body.
- U.S. 9,333,224: Methods for treating bacterial infections with a composition that releases orthosilicic acid in the body.
- U.S. 10,493,097: Approaches for treating specific ulcer types (wounds) with a composition that releases orthosilicic acid in the body.
- U.S. 16/089,613: Composition for bone repair or replacement containing silicate and bone/bone surrogate.
- U.S. 16/670,060 (pending): Pending
- EP 2211868: Silicate solution for treating melanoma
- EP 3305305: Silicate solution for wound healing
- EP 211782776 pending
- In-licensed IP ((UK research and innovation)
- Granted US, EP, AU, JP, Eurasian, CN patents in CA, HK, KR, SG
2) Development of virtual health technology to assist patients in developing countries:
Xcelerate has a strong dedication to closing the healthcare gap in developing countries, starting with a special focus on Africa. By creating virtual health technology, the company aims to make it possible for doctors to reach more people and offer medical care to those who currently have limited access.
To make this possible, Xcelerate has secured a 51% ownership in a startup medical technology and virtual health company AfiyaSasa Africa, LLC (ASA), initiated by the globally recognized Tanzanian Neurosurgeon, Dilan Ellegala. Company helps patients in developing countries talk to doctors through its platform to get the medical care they need. The ASA platform uses smart technology like AI (artificial intelligence) and AR (Augmented Reality), created by AdviNOW. This helps people who live far away from medical help and don’t have many doctors nearby, whether they’re in remote places or cities.Patients can use their cell phones, tablets, or computers to use the system. It lets doctors and medical staff assess their condition, decide the best care, and guide them through the process online. The system even has facial recognition and can remember if the patient has used it before.
The AfiyaSasa Tanzania Project is getting ready to start in various hospitals across the country with the help of its own subsidiary. Each hospital will provide special services and telehealth features as part of this project.
Back in March 2023, Xcelerate took a big step by signing an Agreement to bring its Artificial Intelligence (AI) based health services to The National Hospital of Tanzania, Muhimbili National Hospital, and Mloganzila in Dar es Salaam. This is the largest hospital in East Africa. The Muhimbili National Hospital System is the premier tertiary care hospital system for all of Tanzania, a country with 64 million people. It has around 1,500 beds for patients and serves about 2,000 patients every day.
Just two weeks later, Xcelerate signed another Agreement to introduce its AI-based health services to Haydom Regional Rural Referral Hospital, which is also known as Haydom Lutheran Hospital (“HLH”), in Haydom, Tanzania. HLH is a big hospital with 420 beds and it takes care of 5.7 million people in North Central Tanzania. Every year, HLH helps around 12,635 patients who stay in the hospital and supports about 103,173 patients who visit for outpatient care.
And there’s more to come – two more hospitals will be joining this important project soon.
3) Acquisition of Healthcare and Skincare Companies:
- Ceramedx, a facial cleanser specially formulated for dry, sensitive skin, features ESN’s exclusive RiceramideTR-3. This innovative product harnesses ESN’s natural ceramide technology. (www.ceramedx.com)
- Earth Science Beauty (www.earthsciencebeauty.com) provides a range of plant-based solutions designed for skin, body, and hair care needs.
Strategic Future Plans
These future plans are a testament to Xcelerate’s unwavering dedication to advancing healthcare on multiple fronts. The company’s vision extends beyond the present, encompassing breakthroughs in medical technology, virtual health solutions, and even skincare innovations. By embracing the power of technology and collaboration, Xcelerate aims to address critical healthcare challenges, bridge gaps in medical access, and provide solutions that cater to both physical well-being and self-care. Through these strategic endeavors, Xcelerate is poised to shape a more inclusive and progressive future for healthcare.Xcelerate’s plans go beyond just changing healthcare – they could also lead to more earnings. By offering a mix of medical technology, virtual health, and skincare products, the company is setting itself up to make money from different sources. This smart approach could help Xcelerate grow financially while also making a positive impact on healthcare overall.One of the notable aspects of Xcelerate’s journey is its plan for uplisting to the Nasdaq. The company’s progression from being a Pink Current to OTCQB-listed entity reflects its commitment to transparency and growth. A potential uplisting could offer greater visibility, credibility, and access to a broader investor base. This transition will undoubtedly be closely monitored by investors and market analysts for its implications on the company’s valuation and future prospects.
Corporate Information
Xcelerate holds OTCQB status as indicated on otcmarkets.com under the symbol XCRT.
As of August 15th, 2023, Xcelerate, Inc. presents a well-defined share structure that sheds light on its market dynamics. The company’s authorized shares total 1,000,000,000, while the outstanding shares in circulation amount to 406,446,072. Among these, a float of 113,254,437 shares is available for trading on the market, with the remaining 269,291,635 shares designated as restricted. Company holds a market capitalization of $33,328,578 as of August 15th, 2023
Conclusion
In the world of penny stocks, Xcelerate, Inc. (OTC: XCRT) has emerged as a standout Healthcare Services stock in 2023. Under the leadership of CEO and Director Mike O’Shea, the company has achieved remarkable progress, transitioning from its initial shell status to Pink Current and eventually reaching the esteemed OTCQB tier with ambitions of listing on the New York Stock Exchange. Xcelerate’s diverse initiatives, spanning innovative medical technology, virtual health solutions, and skincare innovations, show a holistic approach to improving healthcare. With a skilled team and strategic partnerships, the company aims not only for financial growth but also to create a positive impact on healthcare. The potential move to the NYSE adds another layer of interest, hinting at exciting times ahead for investors and the industry as a whole.
Make sure you are a subscriber to otcstockz since we will update on Xcelerate, Inc. (XCRT Stock) as new information becomes available.
Read how to buy Penny Stocks : Buying Penny Stocks for Less Than $1? What You Must Understand
Read how to buy Penny Stocks :How to purchase OTC Stocks in 2022?
